drugset
Drugs / Heterologous mRNA booster vaccine
last change May 2024 re-read 2 minutes ago

Heterologous mRNA booster vaccine

Messenger RNA (mRNA)

Developed for
COVID-19
Investigated by
A*Star · Duke-NUS Graduate Medical School · KK Women's and Children's Hospital · Tan Tock Seng Hospital

Trials 1 · a red edge is where a trial was stopped

today NCT05142319 · Ph 4
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT05142319 Oct 2021 → Jun 2023 COVID-19 Tan Tock Seng Hospital Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Heterologous mRNA booster vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142319 ↗
Modality Messenger RNA (mRNA) “two mRNA vaccines (BNT162b2 and mRNA-1273)” PMID 35710572 ↗ Jun 2022
Route Other “Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.” NCT05142319 ↗